INS and Hypoglycemia: Additionally, in small studies in non‐NET patients, intravenous or subcutaneous octreotide was found to be effective in treating sulfonylurea‐induced hypoglycemia in the acute setting,12, 13 thought to be via octreotide's inhibition of insulin release from pancreatic beta cells.